The National Institutes of Health in Bethesda, Md., has suspended production at two facilities that make materials for research participants after an evaluation found the labs were "not in compliance with quality and safety standards, and not suitable for the production of sterile or infused products," according to a statement from NIH.
NIH will also not enroll new patients in any of the affected trails until the problems are resolved, but there is no evidence that any patients have been harmed.
The affected facilities are a National Cancer Institute lab that makes cell therapy products and a National Institute of Mental Health lab that makes positron emission tomography, or PET, materials.
NIH had hired two companies to evaluate all of its facilities that produce sterile or infused products after major issues at the NIH Clinical Center Pharmaceutical Development Section were found last year.
According to NPR, NIH also launched an internal investigation after the problems last year and put together a so-called "red team" to find the underlying cause of safety issues. The team is set to brief an advisory committee Thursday.